Marecos R, Galimberti G, Passardi S, Galimberti RL, Guzmán FA

Language: Spanish
References: 20
Page: 231-236
PDF size: 184.92 Kb.

ABSTRACT

Conventional Photodynamic therapy (PDT) is an attractive treatment minimally invasive and approved for the treatment of actinic keratosis (AK), Bowen’s disease (BD), certain types of basal cell carcinomas (BCC). Also for inflammatory dermatoses, infectious dermatoses and photo-aging. In recent years in the Nordic countries emerged a new form of topical PDT without incubation time and activated with sunlight for the treatment of AK and for the cancerization field , with the advantage of being painless, unlike conventionaland quite painful PDT.
Objectives: To present our experience with daylight photodynamic therapy (DLPDT) for the treatment of facial and scalp AK Grade I, II and III. We evaluated pain, erythema immediately after DLPDT and therapeutic response after 8 weeks.
Methodology: From January till March, in the city of Buenos Aires recruited 13 AK patients with grade I, II and III located in scalp and face. We use methyl aminolevulinate 16% cream (Galderma, Norway) and applied it to the treated area within the the hospital, it was activated by daylight after 2 hours of exposure
Results: In 13 patients a total of 342 AK grade I, II and III were treated. They responded to treatment In a 48%, 51% for grade I, 47% for grade II. The Grade III showed only partial remission. The DLPDT is virtually painless and a mild erythema.
Discussion: The DLPDT is a simple and painless treatment for AK of varying degrees, better response were seen in AK grades I and II. Response dependents on the weather as it does not show efficacy in cloudy or rainy days. It also depends on the intensity of the ultraviolet radiation of day and patient adherence to directions received by the dermatologist.

REFERENCES

1. Morton CA. “Photodynamic therapy in Skin Cancer”. En Rigel DS. Cancer of the Skin, 2a ed, Elsevier, 2001, 497-507.

2. Wiegell SR, Wulf HC, Sxwimies RM, Basset-Seguin N, et al. “Daylight photodynamic therapy for actinic keratosis: an international consensus”. International Society for Photodynamic Therapy in Dermatology. JEADV, 2011.

3. Braathen LR, Morton CA, Basset-Seguin N, Bissonnette R. “Photodynamic therapy for skin field cancerization: an international consensus”. International Society for Photodynamic Therapy in Dermatology. JEADV 2012, 26:1063-1066.

4. Perez-Perez L, García Gavín J, Gilaberte Y. “Terapia fotodinámica con luz de día en España: ventajas y limitaciones”. Actas Dermosifiliogr 2014;105:663-674.

5. Morton CA, Szeimies RM, Sidoroff A. “European guidelines for topical photodynamic therapy part 1: treatment delivery and current indications–actinic keratoses, Bowen’s diseases, basal cell carcinoma”. JEADV 2013, 27:536-544.

6. Marini MA, Marini MG y cols. “Tratamiento no quirúrgicos”. Carcinoma basocelular: Actualización en dermatología. 2ª ed., Alfaomega. 2013, 110-117.

7. Wiegell SR, Fabricius S, Heydenreich J, Enk CD, et al. “Weather conditions and daylight-mediated photodynamic therapy: protoporphyrin IX-weighted daylight doses measured in six geographical locations”. Br J Dematol 2013, 168:186-191.

8. Olsen EA, Abernethy ML, Kulp-Shorten C et al. “A doble blind, vehiclecontrolled study evaluating masoprocol cream in the treatment of actinic keratoses on the head and neck”. J Am Acad Dermatol 1991; 24:738-743.

9. Wiegell SR, Fabricius S, Gniadecka M, Stender IM. “Daylight-mediated photodynamic therapy of moderate to thick actinic keratoses of the face and scalp: a randomized multicentre study”. Br J Dermatol 2012, 166:1327-1332.

10. Braathen LR. “Daylight Photodynamic Therapy in Private Practica in Switzerland: Gain Without Pain”. Acta Derm Venereol 2012; 92:585-663.

11. Smits T, Moor ACE. “New aspects in photodynamic therapy of actinic keratoses”. J. Photochem Photobiol B 2009, 96:159-169.

12. Wiegell SR, Heydenreich J, Fabricius S. “Continuous ultra-low-intensity artificial daylight is not as effective as red LED light in photodynamic therapy of multiple actinic keratoses”. Photodermatol Photoinmunol Photomed 2011, 27:280-285.

13. Wiegell SR, Haedersdal M, Eriksen P, Wulf HC. “Photodynamic therapy of actinic keratoses with 8% and 16% methyl aminolevulinato and home-based daylight exposure: a double-blinded randomized clinical trial”. Br J Dermatol 2009, 160(6):1308-1314.

14. Tarstedt M, Rosdahl I, Berne B, et al. “A randomized multicenter study to compare two treatment regimes of topical methyl aminolevulinate (Metvix®)–PDT in actinic keratosis of the face and scalp”. Acta Derm Venereol 2005; 85:1138-1144.

15. Gilaberte Y, Aspiroz C, Martes MP, et al. “Treatment of refractory fingernail onychomycosis caused by nondermatophyte molds with methylaminolevulinate photodynamic therapy”. J Am Acad Dermatol 2011; 65:669-671.

16. Schweiger ES, Riddle CC, Aires DJ. “Treatment of hidradenitis suppurativa by photodynamic therapy with aminolevulinic acid: Preliminary results”. J Drugs Dermatol 2011; 10: 381-386.

17. Golberg DJ. “Photodynamic therapy in skin rejuvenation”. Clin Dermatol 2008; 26:608-613.

18. Hasson A, Navarrete Dechent C, Nicklas C, et al. “Topical photodynamic therapy with methylaminolevulinate for the treatment of actinic keratosis and reduction of photodamage in organ transplant recipients: A case-series of 16 patients”. Indian J Dermatol Venereol Leprol 2012; 78:448-453.

19. Wolfe CM, Green WH, Cognetta AB, et al. “A possible chemopreventive role for photodynamic therapy in Gorlin syndrome: a report of basal cell carcinoma reduction and review of literature”. Australas J. Dermatol 2013; 54:64-68.

20. Strasswimmer J, Grande DJ. “Do pulsed laser produce an effective photodynamic therapy response”. Lasers Surg Med. 2007; 39:201-202.